Please cite this article as: XIAO LX, WANG ZY, LI JT, WANG HM, HAO YM, ZHOU P, HUANG YL, DENG QJ, HAO YC, YANG N, HAN LZ, YANG Z, JIA PP, QI Y, LIU J. Association of cardiometabolic multimorbidity with all-cause and cardiovascular disease mortality among Chinese hypertensive patients. J Geriatr Cardiol 2024; 21(2): 211−218. DOI: 10.26599/1671-5411.2024.02.003.
Citation: Please cite this article as: XIAO LX, WANG ZY, LI JT, WANG HM, HAO YM, ZHOU P, HUANG YL, DENG QJ, HAO YC, YANG N, HAN LZ, YANG Z, JIA PP, QI Y, LIU J. Association of cardiometabolic multimorbidity with all-cause and cardiovascular disease mortality among Chinese hypertensive patients. J Geriatr Cardiol 2024; 21(2): 211−218. DOI: 10.26599/1671-5411.2024.02.003.

Association of cardiometabolic multimorbidity with all-cause and cardiovascular disease mortality among Chinese hypertensive patients

  • BACKGROUND  Hypertension usually clusters with multiple comorbidities. However, the association between cardiometabolic multimorbidity (CMM) and mortality in hypertensive patients is unclear. This study aimed to investigate the association between CMM and all-cause and cardiovascular disease (CVD) mortality in Chinese patients with hypertension.
    METHODS  The data used in this study were from the China National Survey for Determinants of Detection and Treatment Status of Hypertensive Patients with Multiple Risk Factors (CONSIDER), which comprised 5006 participants aged 19–91 years. CMM was defined as the presence of one or more of the following morbidities: diabetes mellitus, dyslipidemia, chronic kidney disease, coronary heart disease, and stroke. Cox proportional hazard models were used to calculate the hazard ratios (HR) with 95% CI to determine the association between the number of CMMs and both all-cause and CVD mortality.
    RESULTS  Among 5006 participants mean age: 58.6 ± 10.4 years, 50% women (2509 participants), 76.4% of participants had at least one comorbidity. The mortality rate was 4.57, 4.76, 8.48, and 16.04 deaths per 1000 person-years in hypertensive patients without any comorbidity and with one, two, and three or more morbidities, respectively. In the fully adjusted model, hypertensive participants with two cardiometabolic diseases (HR = 1.52, 95% CI: 1.09–2.13) and those with three or more cardiometabolic diseases (HR = 2.44, 95% CI: 1.71–3.48) had a significantly elevated risk of all-cause mortality. The findings were similar for CVD mortality but with a greater increase in risk magnitude.
    CONCLUSIONS  In this study, three-fourths of hypertensive patients had CMM. Clustering with two or more comorbidities was associated with a significant increase in the risk of all-cause and cardiovascular mortality among hypertensive patients, suggesting more intensive treatment and control in this high-risk patient group.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return